Lead-212 PSV359 Therapy for Patients With Solid Tumors — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Lead-212 PSV359 Therapy for Patients With Solid Tumors — Stella

Recruiting

Back to Pancreatic Ductal Adenocarcinoma trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(3 sites)

United States

Saint Louis University, St Louis, Missouri

Nebraska Cancer Specialists, Omaha, Nebraska

University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

Key details

Phase

Early testing / Safety & dosing

Sponsor

Perspective Therapeutics

Enrollment target

~112 participants

Started

April 2025

Primary completion

January 2028

Age range

18 Years – 90 Years

Last updated January 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov